Skojarzona terapia nadciśnienia tętniczego – jakie leki połączyć dla maksymalizacji efektu nefroprotekcyjnego? – komentarz do badania ACCOMPLISH Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2010
Słowa kluczowe:
nadciśnienie tętnicze, przewlekła choroba nerek, benazepril, amlodypina, hydrochlorotiazyd, albuminuria, współczynnik przesączania kłębuszkowego
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nowe rekomendacje dotyczące leczenia nadciśnienia tętniczego zalecają w wielu przypadkach rozpoczynanie terapii od zastosowania dwóch leków. Jest to szczególnie uzasadnione w leczeniu i profilaktyce progresji przewlekłego uszkodzenia nerek, ponieważ nadciśnienie towarzyszące przewlekłej chorobie nerek charakteryzuje się opornością na terapię hipotensyjną i wymaga zazwyczaj zastosowania kilku leków dla osiągnięcia zakładanych celów terapeutycznych. Podstawą leczenia hipotensyjnego o działaniu nefroprotekcyjnym jest według aktualnego stanu wiedzy lek ingerujący w oś renina-angiotensyna-aldosteron: inhibitor enzymu konwertującego angiotensynę lub bloker receptora AT1 dla angiotensyny II. Nie ma jednak jednoznacznych rekomendacji dotyczących wyboru drugiego i kolejnych leków w tej grupie pacjentów. W niniejszym artykule przedstawiono stan wiedzy na temat skojarzonej terapii nadciśnienia tętniczego, która może mieć dodatkowe działanie nefroprotekcyjne.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Stompór, T., Napora, M., & Olszewski, A. (2010). Skojarzona terapia nadciśnienia tętniczego – jakie leki połączyć dla maksymalizacji efektu nefroprotekcyjnego? – komentarz do badania ACCOMPLISH . Medycyna Faktów , 3(3(8), 48-56. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2576
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27: 2121-2158.
2. Safaridis P.A., Bakris G.L.: Resistant hypertension: an overview of evaluation and treatment. J. Am. Coll. Cardiol. 2008; 52: 1749-1757.
3. Safaridis P.A., Li S., Chen S.C. et al.: Hypertension awareness, treatment, and control in chronic kidney disease. Am. J. Med. 2008; 121: 332-340.
4. Plantinga L.C., Miller E.R., Stevens L.A. et al.: Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006. Hypertension 2009; 54: 47-56.
5. Guérin A.P., Pannier B., Métivier F. et al.: Assessment and significance of arterial stiffness in patients with chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2008; 17: 635-641.
6. Ford M.L., Tomlinson L.A., Chapman T.P. et al.: Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension 2010; 55: 1110-1115.
7. Arulkumaran N., Diwakar R., Tahir Z. et al.: Pulse pressure and progression of chronic kidney disease. J. Nephrol. 2010; 23: 189-193.
8. Tonelli M., Gill J., Pandeya S. et al.: Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol. Dial. Transplant. 2002; 17: 1426-1433.
9. Wright J.T., Agodoa L., Contreras G. et al.: Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch. Intern. Med. 2002; 162: 1636-1643.
10. Yusuf S., Teo K.K., Pogub J. et al. (ONTARGET Investigators): Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.
11. Przewłocki T., Kabłak-Ziembicka A., Tracz W. et al.: Prevalence and prediction of renal artery stenosis in patients with coronary and supraaortic artery atherosclerotic disease. Nephrol. Dial. Transplant. 2008; 23: 580-585.
12. Kunz R., Friedrich C., Wolbers M., Mann J.F.: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 2008; 148: 30-48.
13. Fried L., Duckworth W., Hang J.H. et al.: Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin. J. Am. Soc. Nephrol. 2009; 4: 361-368.
14. Parving H.H., Persson F., Lewis J.B. et al.: Aliskiren combined with losartan In type 2 diabetes and nephropathy. N. Engl. J. Med. 2008; 358: 2433-2446.
15. Persson F., Rossing P., Reinhard H. et al.: Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32: 1873-1879.
16. Brenner B.M., Cooper M.E., de Zeeuw D. et al.; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-869.
17. Bakris G.L., Toto R.D., McCullough P.A. et al.; GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators: Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008; 73: 1303-1309.
18. Jamerson K., Weber M.A., Bakris G.L. et al.; ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
19. Bakris G.L., Sarafidis P.A., Weir M.R. et al.; ACCOMPLISH Trial investigators: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181.
20. Ruggenenti P., Perna A., Loliga G. et al.: Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised, controlled trial. Lancet 2005; 365: 939-946.
21. Ruggenenti P., Fassi A., Ilieva A. et al.: Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004; 351: 1941-1951.
22. Bakris G.L., Weir M.R., Secic M. et al.: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004; 65: 1991-2002.
23. Bidani A.K., Griffin K.A.: Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004; 44: 595-601.
24.Hart P., Bakris G.L.: Calcium antagonists: do they equally protect against kidney injury? Kidney Int. 2008; 73: 795-796.
25. Sugano N., Wakino S., Kanda T. et al.: T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int. 2008; 73: 826-834.
26. Zhou X., Matavelli L.C., Ono H., Frohlich E.D.: Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR. Am. J. Physiol. Renal. Physiol. 2005; 289: F871-879.
27. Fujihara C.K., Malheiros D.M., Zatz R.: Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model. Am. J. Physiol. Renal. Physiol. 2007; 292: F1810-1818.
28. Vogt L., Navis G., Koster J. et al.: The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J. Hypertens. 2005; 23: 2055-2061.
29. Parving H.H., Smidt U.M., Hommel E. et al.: Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am. J. Kidney Dis. 1993; 22: 188-195.
30. Onuigbo M.A.C.: Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET – a call for more circumspection. Q. J. Med. 2009; 102: 155-167.
31. Tokmakova M.P., Skali H., Kenchaiah S. et al.: Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation 2004; 110: 3667-3673.
32. Perkovic V., Ninomiya T., Arima H. et al.: Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J. Am. Soc. Nephrol. 2007; 18: 2766-2772.
2. Safaridis P.A., Bakris G.L.: Resistant hypertension: an overview of evaluation and treatment. J. Am. Coll. Cardiol. 2008; 52: 1749-1757.
3. Safaridis P.A., Li S., Chen S.C. et al.: Hypertension awareness, treatment, and control in chronic kidney disease. Am. J. Med. 2008; 121: 332-340.
4. Plantinga L.C., Miller E.R., Stevens L.A. et al.: Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006. Hypertension 2009; 54: 47-56.
5. Guérin A.P., Pannier B., Métivier F. et al.: Assessment and significance of arterial stiffness in patients with chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2008; 17: 635-641.
6. Ford M.L., Tomlinson L.A., Chapman T.P. et al.: Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension 2010; 55: 1110-1115.
7. Arulkumaran N., Diwakar R., Tahir Z. et al.: Pulse pressure and progression of chronic kidney disease. J. Nephrol. 2010; 23: 189-193.
8. Tonelli M., Gill J., Pandeya S. et al.: Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol. Dial. Transplant. 2002; 17: 1426-1433.
9. Wright J.T., Agodoa L., Contreras G. et al.: Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch. Intern. Med. 2002; 162: 1636-1643.
10. Yusuf S., Teo K.K., Pogub J. et al. (ONTARGET Investigators): Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.
11. Przewłocki T., Kabłak-Ziembicka A., Tracz W. et al.: Prevalence and prediction of renal artery stenosis in patients with coronary and supraaortic artery atherosclerotic disease. Nephrol. Dial. Transplant. 2008; 23: 580-585.
12. Kunz R., Friedrich C., Wolbers M., Mann J.F.: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 2008; 148: 30-48.
13. Fried L., Duckworth W., Hang J.H. et al.: Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin. J. Am. Soc. Nephrol. 2009; 4: 361-368.
14. Parving H.H., Persson F., Lewis J.B. et al.: Aliskiren combined with losartan In type 2 diabetes and nephropathy. N. Engl. J. Med. 2008; 358: 2433-2446.
15. Persson F., Rossing P., Reinhard H. et al.: Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32: 1873-1879.
16. Brenner B.M., Cooper M.E., de Zeeuw D. et al.; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-869.
17. Bakris G.L., Toto R.D., McCullough P.A. et al.; GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators: Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008; 73: 1303-1309.
18. Jamerson K., Weber M.A., Bakris G.L. et al.; ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
19. Bakris G.L., Sarafidis P.A., Weir M.R. et al.; ACCOMPLISH Trial investigators: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181.
20. Ruggenenti P., Perna A., Loliga G. et al.: Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised, controlled trial. Lancet 2005; 365: 939-946.
21. Ruggenenti P., Fassi A., Ilieva A. et al.: Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004; 351: 1941-1951.
22. Bakris G.L., Weir M.R., Secic M. et al.: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004; 65: 1991-2002.
23. Bidani A.K., Griffin K.A.: Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004; 44: 595-601.
24.Hart P., Bakris G.L.: Calcium antagonists: do they equally protect against kidney injury? Kidney Int. 2008; 73: 795-796.
25. Sugano N., Wakino S., Kanda T. et al.: T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int. 2008; 73: 826-834.
26. Zhou X., Matavelli L.C., Ono H., Frohlich E.D.: Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR. Am. J. Physiol. Renal. Physiol. 2005; 289: F871-879.
27. Fujihara C.K., Malheiros D.M., Zatz R.: Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model. Am. J. Physiol. Renal. Physiol. 2007; 292: F1810-1818.
28. Vogt L., Navis G., Koster J. et al.: The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J. Hypertens. 2005; 23: 2055-2061.
29. Parving H.H., Smidt U.M., Hommel E. et al.: Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am. J. Kidney Dis. 1993; 22: 188-195.
30. Onuigbo M.A.C.: Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET – a call for more circumspection. Q. J. Med. 2009; 102: 155-167.
31. Tokmakova M.P., Skali H., Kenchaiah S. et al.: Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation 2004; 110: 3667-3673.
32. Perkovic V., Ninomiya T., Arima H. et al.: Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J. Am. Soc. Nephrol. 2007; 18: 2766-2772.